Downregulation of KDM5B produces efficient antileukemic effects in MLL-rearranged AML cells and HL-60 cells, suggesting that KDM5B may be a potential epigenetic target for AML treatment [40, 41]. Here, KDM5B is linked to acute myeloid leukemia.